Showing results (1181-1190 of 4,880) with videos related to

Sort By:
Pageof 488
Urologic Oncology|July 9, 2010
p53 immunohistochemistry in bladder cancer--a new approach to an old questionPeter J Goebell, Susan G Groshen, Bernd J Schmitz-Dräger, et al.
Urologic Oncology|July 9, 2010
Molecular pathways of urothelial development and bladder tumorigenesisMireia Castillo-Martin, Josep Domingo-Domenech, Orit Karni-Schmidt, et al.
Urologic Oncology|July 9, 2010
New concepts of biobanks--strategic chance for uro-oncologyPeter J Goebell, Manuel M Morente
Urologic Oncology|January 14, 2011
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumorsA Kirschenbaum, J P Wang, M Ren, et al.
Urologic Oncology|January 14, 2011
Differential time dependency of antiproliferative and apoptotic effects of taxol in human prostate tumorsC T Chen, J L Au, Y Gan, et al.
Urologic Oncology|January 14, 2011
Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancerR Persad, C Fleming, H D Chern, et al.
Urologic Oncology|January 14, 2011
Sequential whole bladder photodynamic therapy treatments: A preclinical studyU O Nseyo, H Kim, J Debord, et al.
Urologic Oncology|January 14, 2011
Expression of p 16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glandsO J Halvorsen, S Haukaas, P Å Høisæter, et al.
Urologic Oncology|January 14, 2011
The influence of mesenchyme of neonatal seminal vesicle and embryonic urogenital sinus on the morphologic and functional cytodifferentiation of dunning prostatic adenocarcinoma: Roles of growth factors and proto-oncogenesN N Tam, M Phil, Y Z Wang, et al.
Urologic Oncology|January 14, 2011
Phase II evaluation of doxorubicin/vinblastine combined with inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinomaL E Schroder, B A Blumenstein, R L Flanigan, et al.
Pageof 488